Advaxis announces publication of preclinical research with ADXS-PSA

Jun 14 2012

Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.    

This research was conducted in collaboration with Dr. Chandan Guha and his laboratory at Montefiore Medical Center, Bronx, NY. The paper titled "Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer" by Hannan R, Zhang H, Wallecha A, Singh R, Liu L, Cohen P, Alfieri A, Rothman J, and Guha C., has been e-published ahead of print in the journal Cancer Immunology Immunotherapy.

The objective of the study was to determine if the combination of ADXS-PSA immunotherapy and radiation therapy could improve upon the efficacy of either immunotherapy alone or radiation therapy alone in the treatment of mice bearing PSA-expressing TPSA23 tumors, a preclinical model of prostate cancer.

The study showed:

• The combination of ADXS-PSA immunotherapy and radiation therapy resulted in complete regression of established tumors in 60% of mice compared to ≤ 10% complete regression in either of the treatments alone.
• In mice that completely regressed after combination therapy, tumors did not develop upon re-challenge with tumor cells, suggesting the induction of systemic and protective immune memory.
• In addition, combination therapy resulted in increased induction of PSA-specific T cells in the periphery and an increased infiltration of these cells in the tumor microenvironment.

"ADXS-PSA continues to demonstrate activity in models of prostate cancer, confirming our decision to move this construct into clinical development. The potential synergy of ADXS-PSA and radiotherapy observed in this study suggests that ADXS-PSA might be combined with other therapies that show efficacy in this type of tumor," commented Dr. John Rothman, EVP of Science and Operations at Advaxis.